28 September 2021 - - French medical device company Biocorp (PAR: ALCOR) has inked an agreement with Danish pharmaceutical company and diabetes care specialist Novo Nordisk (NYSE: NVO) for the development and distribution (pending successful development) of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes, the company said.

Mallya is a Bluetooth enabled smart add-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software.

Mallya helps people with diabetes maintain a reliable dose log, using technology to help improve understanding and allowing people to dose with confidence.

Most Novo Nordisk's insulins are offered with the FlexTouch pen, and it is part of the launch map for all new insulins. A specific version of Mallya will be developed for FlexTouch, the first prefilled insulin delivery device with no-push-button extension.

Due to the unique dosing mechanism of FlexTouch, the push button does not extend at any dose and allows insulin to be administered by pressing the low injection force button.

The existing Mallya device had to be redesigned to meet the needs of this mechanism, keeping its accuracy and reliability for the patient.

Directly attached on the disposable pre-filled FlexTouch pen, Mallya will allow seamless and efficient dose logging on FlexTouch, which could help people with diabetes and their HCPs to have more personalized conversations about the disease and treatment compliance.

Biocorp will receive an upfront payment and different milestones are defined staging the development phase. Upon successful development, Novo Nordisk plans to distribute the smart device in selected countries, and Biocorp expects to ramp up production volumes from 2022.

Financials and terms of contract are not disclosed.

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has TODAY acquired a leading position in the connected medical device market thanks to Mallya.

This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes.

Available for sale from 2020, Mallya spearheads Biocorp's product portfolio of innovative connected solutions. The company has 70 employees.